Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection - Summary - MDSpire
Advertisement
Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection
To evaluate the efficacy and safety of pimodivir in combination with standard care treatment specifically for high-risk adolescents and adults with influenza A.
Key Findings:
Pimodivir + SoC showed no clinical benefit over placebo + SoC on HRS at day 6 in hospitalized patients.
In high-risk outpatients, pimodivir + SoC demonstrated a shorter median TTR of influenza symptoms compared to placebo + SoC.
Interpretation:
Pimodivir did not provide additional clinical benefits in hospitalized patients but showed potential in reducing symptom duration in high-risk outpatients.
Limitations:
The studies did not demonstrate a significant clinical benefit in hospitalized patients, and the reliance on varying standard of care may affect the generalizability of the results.
Conclusion:
Pimodivir may be beneficial for high-risk outpatients with influenza A, but further investigation is needed to establish its efficacy in hospitalized patients.
Pragmatic cluster randomized crossover study found no statistically significant difference in laboratory-confirmed influenza during the 2023-2024 season
